A combination of ligand SAR and receptor site-directed mutagenesis reveals requirements for antagonist activity at the melanocortin-3 receptor.

Proneth, B., Portillo, F. P., & Haskell-Luevano, C. (2009). A combination of ligand SAR and receptor site-directed mutagenesis reveals requirements for antagonist activity at the melanocortin-3 receptor. Advances in Experimental Medicine and Biology, 611, 319–320. https://doi.org/10.1007/978-0-387-73657-0_142